Abstract
Rationale
Serotonin-1B receptor (5-HT1BR) agonist treatment induces obsessive-compulsive disorder (OCD)-like behaviors including locomotor stereotypy, prepulse inhibition deficits, and delayed alternation disruptions, which are selectively prevented by clinically effective OCD treatment. However, the role of 5-HT1BRs in modulating other repetitive behaviors or OCD-like patterns of brain activation remains unclear.
Objectives
We assessed the effects of 5-HT1BR agonism on digging, grooming, and open field behaviors in mice. We also quantified effects on neuronal activation in brain regions overactivated in OCD. Finally, we assessed whether effects of the 5-HT1BR challenge could be blocked by clinically effective, but not ineffective, drug treatments.
Methods
Mice were tested in open field, dig, and splash tests after acute treatment with saline, 1, 3, 5, or 10 mg/kg RU24969 (5-HT1B/1A agonist). Behavioral effects of RU24969 were also tested following co-treatment with vehicle, 1 mg/kg WAY100635 (5-HT1A antagonist) and 5 or 10 mg/kg GR127935 (5HT1B/D antagonist). Separate mice were behaviorally assessed following chronic pretreatment with vehicle with 10 mg/kg fluoxetine or 20 mg/kg desipramine and acute treatment with saline or 10 mg/kg RU24969. Brains were analyzed for Fos expression in the orbitofrontal cortex, the dorsal striatum, and the cerebellum.
Results
RU24969 induced robust locomotor stereotypy and decreased rearing, digging, and grooming. Effects were blocked by GR127935 but not by WAY100635. RU24969 also increased Fos expression in the dorsal striatum. Chronic fluoxetine, but not desipramine, alleviated 5-HT1BR-induced effects.
Conclusions
We report novel 5-HT1BR-induced behaviors and striatal activation that were alleviated only by clinically effective pharmacological OCD treatment. Studying the mechanisms underlying these effects could provide insight into OCD pathophysiology.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahmari S, Spellman T, Douglass N, Kheirbek M, Simpson H, Deisseroth K, Gordon JA, Hen R (2013) Repeated cortico-striatal stimulation generates persistent OCD-like behavior. Science 340(6137):1234–9. doi:10.1126/science.1234733
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. APA, Arlington
Aronsen D, Webster J, Schenk S (2014) RU 24969-produced adipsia and hyperlocomotion: differential role of 5HT 1A and 5HT 1B receptor mechanisms. Pharmacol Biochem Behav 124:1–4. doi:10.1016/j.pbb.2014.05.008
Baxter LR, Schwartz JM (1992) Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 49(9):681–9. doi:10.1001/archpsyc.1992.01820090009002
Benkelfat C, Nordahl TE (1990) Local cerebral glucose metabolic rates in obsessive-compulsive disorder: patients treated with clomipramine. Arch Gen Psychiatry 47(9):840–8. doi:10.1001/archpsyc.1990.01810210048007
Bromberg-Martin ES, Matsumoto M, Hikosaka O (2010) Dopamine in motivational control: rewarding, aversive, and alerting. Neuron 68(5):815–34. doi:10.1016/j.neuron.2010.11.022
Burguière E, Monteiro P, Feng G, Graybiel AM (2013) Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors. Science 340(6137):1243–1246. doi:10.1126/science.1232380
Chaudhury PK, Deka K, Chetia D (2006) Disability associated with mental disorders. Indian J Psychiatry 48(2):95–101. doi:10.4103/0019-5545.31597
Cheetham S, Heal D (1993) Evidence that RU24969-induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5-HT1B receptor. Br J Pharmacol 110(4):1621–9. doi:10.1111/j.1476-5381.1993.tb14010.x
De Souza RJ, Goodwin GM, Green AR, Heal DJ (1986) Effect of chronic treatment with 5-HT1 agonist (8-OHDPAT and RU 24969) and antagonist (isapirone) drugs on the behavioural responses of mice to 5-HT1 and 5-HT2 agonists. Br J Pharmacol 89(2):377–84. doi:10.1111/j.1476-5381.1986.tb10270.x
Dulawa SC, Grandy DK, Low MJ, Paulus MP, Geyer MA (1999) Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J Neurosci 19(21):9550–6
Dulawa SC, Holick KA, Gundersen B, Hen R (2004) Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29(7):1321–30. doi:10.1038/sj.npp.1300433
Dulawa SC, Hen R (2005) Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 29(4–5):771–8. doi:10.1016/j.neubiorev.2005.03.017
Durand M, Berton O, Aguerre S, Edno L, Combourieu I, Mormède P, Chaouloff F (1999) Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis axis in SHR and WKY rats. Neuropharmacology 38(6):893–907. doi:10.1016/S0028-3908(99)00009-X
Ellingrod VL (1998) Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature. Pharmacotherapy 18(5):936–60. doi:10.1002/j.1875-9114.1998.tb03926.x
Gardner CR (1986) Recent developments in 5HT-related pharmacology of animal models of anxiety. Pharmacol Biochem Behav 24(5):1479–85. doi:10.1016/0091-3057(86)90215-7
Geyer MA, Russo PV, Masten VL (1996) Multivariate assessment of locomotor behavior: pharmacological behavioral analyses. Pharmacol Biochem Behav 25(1):277–88. doi:10.1016/0091-3057(86)90266-2
Geyer MA, Markou A (1995) Animal models of psychiatric disorders. In: Kupfer D, Bloom F (eds) Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp 787–798
Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J (2004) Serotonergic dissection of obsessive-compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 50:200–5. doi:10.1159/000079970
Hollander E (1998) Treatment of obsessive-compulsive spectrum disorders with SSRIs. Br J Psychiatry Suppl 35:7–12
Hoenig K, Hochrein A, Quednow BB, Maier W, Wagner M (2005) Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder. Biol Psychiatry 57:1153–8. doi:10.1016/j.biopsych.2005.01.040
Lalonde R, Strazielle C (2008) Relations between open-field, elevated plus-maze, and emergence tests as displayed by C57/BL6J and BALB/c mice. J Neurosci Methods 171(1):48–52. doi:10.1016/j.jneumeth.2008.02.003
Li Q, Muma NA, van de Kar LD (1996) Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist. J Pharmacol Exp Ther 279(2):1035–42
Lobo MK, Zaman S, Damez-Werno DM, Koo JW, Bagot RC, DiNieri JA, Nugent A, Finkel E, Chaudhury D, Chandra R, Riberio E, Rabkin J, Mouzon E, Cachope R, Cheer JF, Han MH, Dietz DM, Self DW, Hurd YL, Vialou V, Nestler EJ (2013) ΔFosB induction in striatal medium spiny neuron subtypes in response to chronic pharmacological, emotional, and optogenetic stimuli. J Neurosci 33(47):18381–95. doi:10.1523/jneurosci.1875-13.2013
Lucas JJ, Segu L, Hen R (1997) 5-hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. Mol Pharmacol 51(5):755–63. doi:10.1124/mol.51.5.755
Koran LM, Pallanti S, Quercioli L (2001) Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol 11(2):169–72. doi:10.1016/S0924-977X(01)00082-7
Milad MR, Rauch SL (2012) Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci 16(1):43–51. doi:10.1016/j.tics.2011.11.003
Moritz S, Fricke S, Wagner M, Hand I (2001) Further evidence for delayed alternation deficits in obsessive-compulsive disorder. J Nerv Ment Dis 189:562–4. doi:10.1097/00005053-200108000-00012
Paulus MP, Geyer MA (1991) A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology (Berl) 104(1):6–16. doi:10.1007/BF02244547
Peroutka SJ (1986) Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B, and 5-HT1C binding sites in rat frontal cortex. J Neurochem 47:529–40. doi:10.1111/j.1471-4159.1986.tb04532.x
Saxena S, Brody AL, Maidment KM, Dunkin JJ (1999) Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 21(6):683–93. doi:10.1016/S0893-133X(99)00082-2
Saxena S, Rauch SL (2000) Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am 23(3):563–86. doi:10.1016/S0193-953X(05)70181-7
Shanahan NA, Holick Pierz KA, Masten VL, Waeber C, Ansorge M, Gingrich JA, Geyer MA, Hen R, Dulawa SC (2009) Chronic reductions in serotonin transporter function prevent 5-HT1B induced behavioral effects in mice. Biol Psychiatry 65(5):401–8. doi:10.1016/j.biopsych.2008.09.026
Shanahan N, Velez L, Masten V, Dulawa S (2011) Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice. Biol Psychiatry 70:1039–48. doi:10.1016/j.biopsych.2011.07.03
Shmelkov SV, Hormigo A, Jing D, Proenca CC (2010) Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med 16(5):598–602
Torres AR, Prince MJ, Bebbington PE, Bhugra D, Brugha TS, Farrell M, Jenkins R, Lewis G, Meltzer H, Singleton N (2006) Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000. Am J Psychiatry 163(11):1978–85
Welch JM, Lu J, Rodriguiz RM, Trotta NC, Peca J, Ding JD, Feliciano C, Chen M, Adams JP, Luo J, Dudek SM, Weinberg RJ, Calakos N, Wetsel WC, Feng G (2007) Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 448(7156):894–900. doi:10.1038/nature06104
Woehrle NS, Klenotich SJ, Jamnia N, Ho EV, Dulawa SC (2013) Effects of chronic fluoxetine treatment on serotonin 1B receptor-induced deficits in delayed alternation. Psychopharmacology (Berl) 227(3):545–5. doi:10.1007/s00213-013-2985-0
Wong K, Elegante M, Bartels B, Elkhayat S, Tien D, Roy S, Goodspeed J, Suciu C, Tan J, Grimes C, Chung A, Rosenberg M, Gaikwad S, Denmark A, Jackson A, Kadri F, Chung KM, Stewart A, Gilder T, Beeson E, Zapolsky I, Wu N, Cachat J, Kalueff AV (2010) Analyzing habituation responses to novelty in zebrafish (Danio rerio). Behav Brain Res 208(2):450–7. doi:10.1016/j.bbr.2009.12.023
Zor R, Szechtman H, Hermesh H, Fineberg NA, Eilam D (2011) Manifestation of incompleteness in obsessive-compulsive disorder (OCD) as reduced functionality and extended activity beyond task completion. PLoS ONE 6(9), e25217. doi:10.1371/journal.pone.0025217
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ho, E.V., Thompson, S.L., Katzka, W.R. et al. Clinically effective OCD treatment prevents 5-HT1B receptor-induced repetitive behavior and striatal activation. Psychopharmacology 233, 57–70 (2016). https://doi.org/10.1007/s00213-015-4086-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-015-4086-8